PDCD1 and neoplasm: Immunotherapy can activate the body’s immune system to identify and eliminate these residual cancer cells, thereby precluding recurrence or metastasis.23 In addition, immunotherapy (such as PD-1/programmed death-ligand 1 inhibitors) activates immune effector cells, such as T cells, enabling the body to generate immune memory against tumor antigens.